Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0025202 (melanoma)
 69,561 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Two tightly linked recombination activating genes, RAG-1 and RAG-2, are involved in VDJ recombination of the immune system. Although these genes were originally thought to be expressed exclusively in precursor B and T cells, RAG-1 transcripts were recently found in the murine central nervous system (CNS) [Chun et al., Cell 6, 189, (1991)]. We found that the RAG-2 gene was expressed in CNS tumor cell lines, melanoma (B-16) and skin fibroblast (A9). RAG-1 expression was not found in any non-lymphoid cell lines examined including CNS tumor cell lines. Another VDJ recombination-related gene RBP-Jk was expressed in all tumor cell lines examined. It remains to be seen whether expression of RAG-1 and RAG-2 in CNS is abortive or functionally important.
 ...
PMID:Expression of the RAG-2 gene in murine central nervous system tumor cell lines. 168 34

An antigen specifically expressed on the surface of plasma membrane of B-lymphocytes and Reed-Sternberg cells was identified using a newly developed monoclonal antibody produced by immunization by BALB/c mouse with a Hodgkin's cell line (HDLM-3). The antibody was termed anti-BLA.36 (B lymphocyte antigen.36) to indicate its predominant reactivity and the molecular weight of the corresponding antigen. By using immunoperoxidase techniques, expression of BLA.36 was detected on Hodgkin's, B-, and pre-B-cell lines, but not on other hematopoietic, melanoma, or carcinoma cell lines. In normal tissues, BLA.36 was detectable predominantly on cells in the germinal center and mantle zone of reactive follicles in lymph nodes and spleen. In hematopoietic malignancy, BLA.36 was detectable on the surface of Reed-Sternberg cells, mononuclear Hodgkin's cells, and also on malignant cells of B-cell lineage. Under these conditions, T-lymphocytes, histiocytes, granulocytes, macrophages, stromal cells in lymphoid tissue, and both normal and neoplastic epithelial cells were consistently negative for the expression of the antigen, with the single exception of a variable proportion of Kupffer cells in normal liver. Biochemical and immunological analyses indicate that BLA.36 is distinct from previously identified antigens of hematopoietic cell lineage, including CD20 and CD75 (LN2) which have similar molecular weights. When BLA.36-positive cell lines were cultured in the presence of the antibody, cell growth was adversely affected. Such an effect was eliminated by removal of the antibody from the culture, suggesting a possible growth-related function of the antigen. Anti-BLA.36 may serve as a probe to study growth-related functions of the corresponding antigen during normal growth of the B-lymphocyte, as well as in the neoplastic proliferations occurring in Hodgkin's disease and antigen-positive B-cell lymphomas. Finally, the antibody has already demonstrated its usefulness for the identification of Reed-Sternberg and Hodgkin's cells, and also normal and malignant B-lymphocytes in frozen as well as formalin- or B5-fixed/paraffin-embedded tissue sections.
 ...
PMID:Characterization of a cell surface molecule expressed on B-lymphocytes and Hodgkin's cells. 168 14

The dynamics of lymphoid cell subpopulations in bronchoalveolar lavage fluid (BALF) and the systemic lymphoid organs of mice after intravenous injection of B16 melanoma cells were examined with a fluorescence-activated cell sorter. The lymphoid cell subpopulations of BALF and mediastinal lymph nodes showed significant changes in numbers and proportions, while those of other lymphoid organs including inguinal lymph nodes, thymus and spleen, showed little change. In week 1, the cells with a Thy-1.2+, Lyt-1+, L3T4-, Lyt-2- phenotype and asialo-Gm1+ cells in BALF significantly increased and L3T4+ cells slightly increased in number. By week 3, the numbers of Lyt-2+ cells in BALF markedly increased in number (by about 90 times) compared with controls. The number of Thy-1.2+ cells in mediastinal lymph nodes also increased significantly by week 3. Mice that had been pretreated with an immunosuppressive dose of cyclophosphamide were also inoculated intravenously with B16 melanoma cells. In these mice, a significantly increased number of pleural tumors developed and the number of Thy-1.2+ cells in BALF was markedly reduced from week 1 to 3. The results indicate that L3T4 and Lyt-2 double negative T-cells and natural killer (NK) cells may be generated and/or mobilized to the lung in an early phase of experimental metastasis of B16 melanoma cells and that at a later stage, when multiple metastases develop, T-cells with a Lyt-2+ phenotype markedly increase, probably as an expression of a host reaction against proliferating metastatic tumor cells.
 ...
PMID:In vivo dynamics of pulmonary lymphoid cell subpopulations generated against pulmonary metastasis: evaluation by bronchoalveolar lavage fluid. 169 54

The monoclonal antibody HMB-45 is a highly specific and sensitive marker of malignant melanoma. Rarely, however, aberrant reactivity to nonmelanocytic tumors has been observed. We report an immunoblastic lymphoma of B-cell phenotype that reacted with HMB-45 in a 70-year-old white woman. To our knowledge, this is the first report of HMB-45-positive malignant lymphoma (excluding plasmacytoma). Of an additional 13 cases of benign and malignant lymphoid tissue, only benign plasma cells in one case reacted with HMB-45.
 ...
PMID:HMB-45-positive malignant lymphoma. A case report with literature review of aberrant HMB-45 reactivity. 152 50

We have examined the ability of bryostatin 1 to inhibit the in vitro growth and in vivo development of a panel of four murine tumors of diverse tissue origins. A wide range of antiproliferative responses was observed for the four tumors. At 100 ng/ml the in vitro growth of the Renca renal adenocarcinoma, the B16 melanoma, the M5076 reticulum cell sarcoma, and the L10A B-cell lymphoma were inhibited by 0, 40, 40, and 94% respectively. All three cell lines sensitive to bryostatin in vitro responded to multiple dose, 1 microgram/injection/day in vivo i.p., bryostatin therapy. Only the in vitro resistant Renca tumor failed to respond to bryostatin in vivo. The correlation between in vitro and in vivo antitumor efficacy suggests a direct mechanism of antitumor activity for bryostatin. Both local regional therapy (M5076 i.p.) and systemic therapy (B16 lung metastases and L10A s.c. tumors) with bryostatin were successful at prolonging survival time. Multiple i.p. doses of bryostatin at a minimum level of 0.5-1.0 microgram/injection were required to observe significant in vivo antitumor effects. The success of in vivo administration of bryostatin in mice bearing 8-10-mm s.c. masses of L10A lymphoma (5-10 x 10(9)) and our further observation that five of a panel of six human B-cell lymphoma cell lines were sensitive to the growth inhibitory effects of bryostatin in vitro suggest that bryostatin may be effective in treating lymphoid malignancies in humans.
 ...
PMID:Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. 172 68

Experienced ophthalmologists who appropriately employ ancillary diagnostic testing, including fluorescein angiography, ocular ultrasonography, MRI, and fine needle aspiration biopsy, are remarkably accurate in the diagnosis of intraocular neoplasms. Recognizing the classic clinical features of the more commonly encountered lesions, such as choroidal melanoma, choroidal nevus, metastatic carcinoma to choroid, lymphoid tumors, and circumscribed choroidal hemangioma, and understanding the applicability and limitations of the various diagnostic tests are the keys to accurate detection.
 ...
PMID:Differential diagnosis of choroidal neoplasms. 182 11

The purpose of this study was to identify human melanoma-associated Ag (MAA) that are immunogenic in patients, because these molecules may be useful immunogens to implement active specific immunotherapy. To this end, an expression cDNA library constructed from the human melanoma cell line A375 was screened with sera from patients with melanoma. A 1029-bp cDNA (designated D-1) was isolated. Its nucleotide sequence showed no significant homology with viral and mammalian sequences stored in GE-NETYX. cDNA D-1 hybridized to a 2.0-kb mRNA species from human melanoma, neuroblastoma, erythroleukemia, B lymphoid, and T lymphoid cell lines but not from a renal carcinoma cell line, PBL, and cultured skin fibroblasts. The D-1 clone produced a fusion protein that displayed a significantly higher reactivity with sera from patients with melanoma than from healthy controls. Furthermore, D-1 fusion protein induced in mice antibodies that immunoprecipitated a 50-kDa component from cultured human melanoma cells. The structural properties of D-1 MAA are different from those of previously described MAA. These results suggest that the approach we have applied may be useful to identify novel MAA expressed by melanoma cells. Furthermore, the immunogenicity of recombinant D-1 protein suggests that it may be a valuable immunogen to implement active specific immunotherapy in patients with melanoma, if additional experiments show that it has the appropriate tissue distribution.
 ...
PMID:Cloning and in vitro expression of a melanoma-associated antigen immunogenic in patients with melanoma. 186 Oct 72

The value of morphologic features to be used prognosing dissemination and survival in skin malignant melanoma is discussed. Single-factor statistical analysis showed tumor thickness, extent of invasion or local spreading, clinico-morphologic pattern, lymphoid-plasmocytic infiltration, mitotic activity and cell composition to be the most reliable in predicting survival and dissemination in clinical stage I malignant melanoma of the skin. These parameters should be evaluated at microscopic evaluation of the tumor. Two-, five- and ten-year prognosis was obtained by multifactorial analysis yielding credibilities of 86.2, 78.5 and 71% for survival and 61.5, 68.7 and 74.3% for lethality, respectively.
 ...
PMID:[Morphological prognostic criteria in skin melanoma]. 203 22

The amount and distribution of negatively charged sites of different cells (human fibroblasts, B16 melanoma cells, a human lymphoid leukemic cell type) were investigated. In the non-irradiated fibroblasts and B16 melanoma cells the negatively charged sites were localized mainly on apical and lateral surfaces as well as in a polarized manner. However, negatively charged sites on the control human lymphoid leukemic cells often have patched distribution. It was demonstrated that the amount and distribution of negatively charged sites on primary human fibroblasts and B16 melanoma cells changed upon ionizing radiation. However, the topology of negative charges on investigated human leukemic cell membrane did not change.
 ...
PMID:Electron microscopic studies on radiation-induced changes of cell surface negative charges. 208 93

A begun started Italian multicentric hospital-based case-control study aimed at detecting carcinogenic risk associated with pesticides exposure is presented. During a 2 year period, incident cases of cancer of various sites in adults of both sexes will be identified in five hospitals used by residents of five Italian rural areas (Asti, Imola, Pescia, Pistoia, Grosseto). Selected sites include the following: lip, oral cavity and oropharynx, oesophagus, stomach, colon-rectum, liver, biliary ducts, pancreas, larynx, lung, soft tissue, skin melanoma, skin other than melanoma, breast, uterus, ovary, prostate, bladder, kidney, thyroid, and lymphoid tissue. Trained personnel will interview patients about their total work experience, with special emphasis on activities in agriculture. Other relevant information to be collected includes pathological anamnesis and smoking habits. A team of coders will analyse the occupational histories using an a priori job-exposures matrix (JEM). The JEM will be specific with respect to type of agricultural production, calendar years, geographic location and pesticides. Each cancer site will be compared with a selected pool of the other sites. This investigation is expected to provide information on a range of associations between cancer of various sites and individual pesticides or mixed exposures. The study can be seen as a pilot study which could be replicated in other areas.
 ...
PMID:Epidemiologic study for the evaluation of the cancerogenic risk associated with pesticides. 210 Jul 64


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>